Searle/Invitron TPA agreement
Modification changes Searle's license to Invitron's proprietary technology pertaining to the manufacture of TPA from an exclusive license to a non-exclusive one. The alteration allows Invitron to enter into additional third-party TPA relationships. In addition, Invitron's rights to specific TPA products were reconveyed to Invitron, which has agreed to pay Searle up to $ 7 mil. over a 10-year period for future TPA product sales.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.